Europe PMC
Nothing Special   »   [go: up one dir, main page]

Europe PMC requires Javascript to function effectively.

Either your web browser doesn't support Javascript or it is currently turned off. In the latter case, please turn on Javascript support in your web browser and reload this page.

This website requires cookies, and the limited processing of your personal data in order to function. By using the site you are agreeing to this as outlined in our privacy notice and cookie policy.

Sorafenib in patients with Child-Pugh class A and B advanced hepatocellular carcinoma: a prospective feasibility analysis.

Show less

Author information

Affiliations

  • 1. Medical Oncology and Haematology Unit, Humanitas Cancer Center, Istituto Clinico Humanitas, IRCCS, Rozzano.
      Authors
    • Pressiani T 1
    • Rimassa L 1
    • Carnaghi C 1
    • Tronconi MC 1
    • Locopo N 1
    • Naimo S 1
    • Santoro A 1
    (7 authors)
  • 2. Medical Oncology, Arcispedale Santa Maria Nuova, IRCCS, Reggio Emilia.
      Authors
    • Boni C 2
    • Banzi M 2
    • Fanello S 2
    (3 authors)
  • 3. Department of Oncology and Hematology, Ospedali Riuniti di Bergamo, Bergamo.
      Authors
    • Labianca R 3
    (1 author)
  • 4. Division of Gastroenterology and Transplant Hepatology, Department of Medicine, Ospedali Riuniti di Bergamo, Bergamo.
      Authors
    • Fagiuoli S 4
    • De Giorgio M 4
    (2 authors)
  • 5. Oncology Division, Azienda Ospedaliero-Universitaria, Parma.
      Authors
    • Salvagni S 5
    (1 author)
    • Show all (14)

ORCIDs linked to this article

Show all (13)

Annals of Oncology : Official Journal of the European Society for Medical Oncology, 05 Oct 2012, 24(2):406-411
https://doi.org/10.1093/annonc/mds343 PMID: 23041587 

Abstract 

Background

Sorafenib has shown survival benefits in patients with advanced hepatocellular carcinoma (HCC) and Child-Pugh (CP) class A liver function. There are few prospective data on sorafenib in patients with HCC and CP class B.

Patients and methods

A consecutive prospective series of 300 patients with CP class A or B HCC were enrolled in a dual-phase trial to determine survival and safety data according to liver function (class A or B) in patients receiving oral sorafenib 800 mg daily. [Results of this study were presented in part at the ASCO 2012 Gastrointestinal Cancers Symposium, 19-21 January 2012. J Clin Oncol 2012; 30 (Suppl 4): abstract 306.]

Results

Overall progression-free survival (PFS), time to progression (TTP) and overall survival (OS) were 3.9, 4.1 and 9.1 months, respectively. For patients with CP class A versus B status, PFS was 4.3 versus 2.1 months, TTP was 4.2 versus 3.8 months and OS was 10.0 versus 3. 8 months. Extrahepatic spread was associated with worse outcomes but taken together with CP class, liver function played a greater role in reducing survival. Adverse events for the two CP groups were similar.

Conclusion

Although patients with HCC and CP class B liver function have poorer outcomes than those with CP class A function, data suggest that patients with CP class B liver function can tolerate treatment and may still benefit from sorafenib.

Full text links 

Read article at publisher's site: https://doi.org/10.1093/annonc/mds343

Read article for free, from open access legal sources, via Unpaywall: https://academic.oup.com/annonc/article-pdf/24/2/406/13789051/mds343.pdfUnpaywall

References 

Articles referenced by this article (22)

Show 10 more references (10 of 22)

Citations & impact 

Impact metrics

92
Citations
Jump to Citations

Citations of article over time

Alternative metrics

Altmetric item for https://www.altmetric.com/details/1196394
Altmetric
Discover the attention surrounding your research
https://www.altmetric.com/details/1196394

Article citations

Go to all (92) article citations

Similar Articles 

To arrive at the top five similar articles we use a word-weighted algorithm to compare words from the Title and Abstract of each citation.

Funding 

Funders who supported this work.

Bayer Italy